S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Biden’s Big Lie… (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Biden’s Big Lie… (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Biden’s Big Lie… (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Biden’s Big Lie… (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Biden’s Big Lie… (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Biden’s Big Lie… (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Biden’s Big Lie… (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Biden’s Big Lie… (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:BTAI

BioXcel Therapeutics - BTAI Stock Forecast, Price & News

$18.66
+0.06 (+0.32%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$18.34
$19.27
50-Day Range
$17.70
$33.24
52-Week Range
$8.80
$34.13
Volume
438,302 shs
Average Volume
716,396 shs
Market Capitalization
$541.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.33

BioXcel Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
185.8% Upside
$53.33 Price Target
Short Interest
Bearish
15.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.13
Upright™ Environmental Score
News Sentiment
0.29mentions of BioXcel Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.77 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.79) to ($4.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

358th out of 996 stocks

Pharmaceutical Preparations Industry

166th out of 484 stocks


BTAI stock logo

About BioXcel Therapeutics (NASDAQ:BTAI) Stock

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in developing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. It also focuses on utilizing cutting-edge technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Stock News Headlines

Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $66.00
BTAI: Important Data Readouts in 2Q23…
BioXcel Therapeutics (NASDAQ:BTAI) Trading Down 5.3%
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Q4 2022 BioXcel Therapeutics Inc Earnings Call
Earnings Preview: BioXcel Therapeutics
Mizuho Securities Keeps Their Buy Rating on Bioxcel Therapeutics (BTAI)
Expert Ratings for BioXcel Therapeutics
See More Headlines
Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTAI Company Calendar

Last Earnings
3/09/2023
Today
4/01/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BTAI
Fax
N/A
Employees
89
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$53.33
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+185.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$-165,760,000.00
Pretax Margin
-44,201.87%

Debt

Sales & Book Value

Annual Sales
$380,000.00
Book Value
$2.74 per share

Miscellaneous

Free Float
18,276,000
Market Cap
$541.33 million
Optionable
Not Optionable
Beta
1.21

Social Links


Key Executives

  • Vimal D. MehtaVimal D. Mehta
    President, Chief Executive Officer & Director
  • Richard I. Steinhart
    Chief Financial & Accounting Officer, Senior VP
  • Frank D. Yocca
    Chief Scientific Officer & Senior Vice President
  • Vincent J. O'Neill
    Chief Medical Officer & Senior Vice President
  • Javier Rodriguez
    Secretary, Chief Legal Officer & Senior VP













BTAI Stock - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTAI shares.
View BTAI analyst ratings
or view top-rated stocks.

What is BioXcel Therapeutics' stock price forecast for 2023?

8 Wall Street analysts have issued twelve-month price objectives for BioXcel Therapeutics' shares. Their BTAI share price forecasts range from $22.00 to $80.00. On average, they expect the company's stock price to reach $53.33 in the next year. This suggests a possible upside of 185.8% from the stock's current price.
View analysts price targets for BTAI
or view top-rated stocks among Wall Street analysts.

How have BTAI shares performed in 2023?

BioXcel Therapeutics' stock was trading at $21.48 at the beginning of 2023. Since then, BTAI stock has decreased by 13.1% and is now trading at $18.66.
View the best growth stocks for 2023 here
.

When is BioXcel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our BTAI earnings forecast
.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its earnings results on Thursday, March, 9th. The company reported ($1.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.49) by $0.46. The company earned $0.24 million during the quarter, compared to analysts' expectations of $1.08 million. During the same quarter in the previous year, the firm posted ($0.93) EPS.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $18.66.

How much money does BioXcel Therapeutics make?

BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $541.33 million and generates $380,000.00 in revenue each year. The company earns $-165,760,000.00 in net income (profit) each year or ($5.91) on an earnings per share basis.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com.

This page (NASDAQ:BTAI) was last updated on 4/2/2023 by MarketBeat.com Staff